Interview with portfolio company Enthera Pharmaceuticals on patented selective inhibitor molecules

July 26, 2021

JDRF T1D Fund Managing Director Katie Ellias sat down with Giovanni Amabile and Paolo Fiorina of Enthera Pharmaceuticals to discuss how the company was started and how they are setting a new treatment paradigm for autoimmune disorders, like T1D, with their patented selective inhibitor molecules.